Collaborations & Alliances

Sanofi, Regeneron Accelerate Cemiplimab/Dupilumab Programs



Increases investment in cemiplimab to $1.64 billion, will submit dupilumab sBLA for uncontrolled, persistent asthma 


Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi and Regeneron Pharmaceuticals will expand their investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. This strategic investment will allow the companies to evaluate cemiplimab and dupilumab in broad clinical development programs.

   The companies will increase their investment in cemiplimab to $1.64 billion, an increase of approximately $1 billion over the initial 2015 agreement a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters